Bradley Corr
University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bradley Corr as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:20 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06856499 · Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerUniversity of Colorado, Denver · recruiting · Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT05887609 · An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibUniversity of Colorado, Denver · recruiting · Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT05649956 · Letrozole in Uterine LeiomyosarcomaGOG Foundation · recruiting · Uterine Leiomyosarcoma · study chair
- Ph2NCT03617679 · Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerUniversity of Colorado, Denver · completed · Metastatic Endometrial Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancerR01CA288651 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2024 to 2026 · $1,201,333 awarded in 2026Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Genomics Shared ResourceP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · fiscal years 2009 to 2026Named on NCT03617679
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:20 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 119 citationsRCR 7.2
- Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.J Immunother Cancer · 202069 citationsRCR 2.9
- Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.J Clin Oncol · 202463 citationsRCR 6.5
- 50 citationsRCR 10.7
- Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.J Clin Oncol · 202242 citationsRCR 2.7
- Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).Clin Cancer Res · 202527 citationsRCR 6.1
- Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.Gynecol Oncol · 202525 citationsRCR 6.0
- Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.Gynecol Oncol · 202424 citationsRCR 2.4
- 21 citationsRCR 4.1
- Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.Clin Cancer Res · 202020 citationsRCR 0.6